WO2005099484A1 - Produit a phase continue aqueuse comprenant un sterol ou un stanolester et un tocopherol - Google Patents

Produit a phase continue aqueuse comprenant un sterol ou un stanolester et un tocopherol Download PDF

Info

Publication number
WO2005099484A1
WO2005099484A1 PCT/EP2005/002878 EP2005002878W WO2005099484A1 WO 2005099484 A1 WO2005099484 A1 WO 2005099484A1 EP 2005002878 W EP2005002878 W EP 2005002878W WO 2005099484 A1 WO2005099484 A1 WO 2005099484A1
Authority
WO
WIPO (PCT)
Prior art keywords
tocopherol
fatty acid
sterol
water continuous
acid ester
Prior art date
Application number
PCT/EP2005/002878
Other languages
English (en)
Inventor
Ingeborg Sonja Viktor Heetvelde
Michel Mellema
Original Assignee
Unilever N.V.
Unilever Plc
Hindustan Lever Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever N.V., Unilever Plc, Hindustan Lever Limited filed Critical Unilever N.V.
Priority to EP05716179A priority Critical patent/EP1742545A1/fr
Priority to AU2005232369A priority patent/AU2005232369A1/en
Publication of WO2005099484A1 publication Critical patent/WO2005099484A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols

Definitions

  • Water continuous product comprising sterol or stanolester and a tocopherol
  • the invention relates to water continuous products such as milk and yoghurt comprising a sterol or stanol fatty acid ester and an antioxidant comprising tocopherol.
  • Food products for lowering cholesterol levels in blood are known for several years.
  • Commercial products that contain ingredients that influence blood cholesterol lowering when daily consumed are for example Becel pro.activTM and BenecolTM.
  • ingredients on which the cholesterol lowering effect is based are sterol fatty acid ester and stanol fatty acid ester. These were initially included in products rich in fat such as margarine. One of the reasons for this was that their incorporation in low fat products was considered difficult .
  • WO-A- 99/44442 relates to stable, homogeneous, emulsifier free suspensions of sterol compounds.
  • EP-A-1212945 discloses dairy-based beverages fortified with stanolester for cholesterol lowering. The amount of stanolester is from 0.2 to about 2 wt%.
  • tocopherol wherein the amount of y- or ⁇ - tocopherol is at least 60 wt% of the total weight of tocopherol, leads to surprisingly good products which do not suffer so much from the development of off taste.
  • WO-A-02/07235 discloses anti-inflammatory compositions comprising sterols and tocotrienols or polyphenols.
  • the preferred tocotrienols are alpha, beta, gamma and delta tocotrienols .
  • WO-A-02/060272 discloses edible oils comprising at least one of free sterol or steryl ester and preferably a compound that reduces cholesterol synthesis in a human patient, such as at least one tocotrienol .
  • WO-A-99/25361 discloses hypocholesteroaemic preparations comprising stenolester and preferably a tocopherol .
  • the most preferred tocopherol is alpha-tocopherol .
  • the invention relates to a water continuous product comprising up to 10 wt% fat, a sterol and/or stanol fatty acid ester, and a tocopherol comprising gamma and/or delta tocopherol , wherein the amount of ⁇ , ⁇ - tocopherol is at least 60wt% of the total amount of tocopherol .
  • the invention relates to water continuous products.
  • the products comprise a continuous aqueous phase in which other ingredients may be present.
  • these other ingredients are dissolved, dispersed or emulsified in the aqueous phase.
  • the continuous phase is formed by the fat phase such as in butter or margarine.
  • the dispersed phase is water in the form of droplets emulsified in the fat phase.
  • the products according to the invention comprise a sterol and/or stanol fatty acid ester.
  • Sterols or phytosterols also known as plant sterols or vegetable sterols can be classified in three groups, 4-desmethylsterols, 4-monomethylsterols and 4 , 4 ' -dimethylsterols .
  • oils they mainly exist as free sterols and sterol esters of fatty acids although sterol glucosides and acylated sterol glucosides are also present.
  • esterified sterol or stanol is selected from the group comprising fatty acid ester of ⁇ -sitosterol, ⁇ - sitostanol, campesterol, campestanol, stigmasterol , brassicasterol, brassicastanol or a mixture thereof.
  • the sterols or stanols are esterified with a fatty acid.
  • the sterols or stanols are esterified with one or more C2-22 fatty acids.
  • C 2 - 22 fatty acid refers to any molecule comprising a C 2 - 22 main chain and at least one acid group.
  • the C2- 22 main chain may be partially substituted or side chains may be present.
  • the C2-2 2 fatty acids are linear molecules comprising one or two acid group (s) as end group (s). Most preferred are linear C 8 . 22 fatty acids as these occur in natural oils.
  • Suitable examples of any such fatty acids are acetic acid, propionic acid, butyric acid, caproic acid, caprylic acid, capric acid.
  • Other suitable acids are for example citric acid, lactic acid, oxalic acid and maleic acid.
  • Most preferred are myristic acid, lauric acid, palmitic acid, stearic acid, arachidic acid, behenic acid, oleic acid, cetoleic acid, erucic acid, elaidic acid, linoleic acid and linolenic acid.
  • a mixture of fatty acids may be used for esterification of the sterols or stanols.
  • a mixture of fatty acids may be used for esterification of the sterols or stanols.
  • the fatty acid in the esterified sterol or stanol is derived from sunflower oil, rapeseed oil, safflower oil, coconut oil, or a mixture thereof.
  • the fatty acid in the esterified sterol or stanol is derived from sunflower oil .
  • the products comprise a combination of a sterol fatty acid ester and a stanol fatty acid ester.
  • the products comprise unesterified "free” , sterol or stanol in addition to the esterified sterol or stanol.
  • the total amount of sterol and stanol fatty acid ester is preferably from 0.1 to 10 wt%. More preferred, the amount is from 0.5 to 5 wt%, most preferred from 2 to 5 wt% on total product weight.
  • the products comprise a tocopherol .
  • the tocopherol is selected from the group comprising ⁇ -, ⁇ -, ⁇ - # ⁇ - tocopherol .
  • Tocopherols are derivatives of 2-methyl-6-chromanol with an attachment of a saturated 16-carbon isoprenoid chain at C-2.
  • the structures of ⁇ - , ⁇ - , ⁇ , and ⁇ - tocopherol are presented in figure 1.
  • the level of tocopherol in a product may be obtained by routine measures including extraction of tocopherols from the samples, followed by quantification using HPLC.
  • Tocopherols are naturally present in oil seeds, grains, leaves, and other green parts of higher plants. Suitable sources of tocopherol are e.g. soy bean and corn oil.
  • At least 60 wt%, preferably at least 70 wt%, more preferred at least 80 wt%, even more preferred at least 94 wt% is in the form of ⁇ - , ⁇ - tocopherol .
  • the total amount of y-, ⁇ - tocopherol is at least 60 wt% on the total weight of tocopherol . It was found that products comprising sterol or stanol ester, especially those of sunflower oil, showed highly improved taste stability and less development of off flavour when using this specific tocopherol composition.
  • the tocopherol comprises at least 60wt% ⁇ tocopherol , even more preferred from 60 to 95 wt% ⁇ -tocopherol .
  • the total amount of tocopherol to achieve the desired level of off taste reduction is preferably from 10 to 50.000 ppm, more preferred from 10 to 5000 ppm, more preferred from 10 to 1000 ppm, even more preferred from 10 to 500 ppm, most preferred from 50 to 500 ppm on total product.
  • the products according to the invention comprise up to 10% fat. This implies that the products may also be fat free.
  • Preferred products are selected from the group comprising drinks such as milk or yoghurt drinks, yoghurts, creams, liquid products based on fruit and protein, such as fusion drinks.
  • the fat may be of any origin. Suitable fats therefore include vegetable fat such as sunflower oil, rapeseed oil, olive oil, coconut oil, safflower oil and dairy fat.
  • Preferred products comprise dairy fat, preferably in an amount from 20 to 80 wt% on total fat. Most preferred products comprise a combination of dairy fat and vegetable fat.
  • the dairy fat may be added as such or may be part of any of the ingredients that are included in the product such as milk proteins or cream.
  • the products comprise further ingredients such as thickeners, emulsifier, sugar, protein, taste and flavour modifiers, fruit or fruit concentrate, acidifier, cultures.
  • further ingredients such as thickeners, emulsifier, sugar, protein, taste and flavour modifiers, fruit or fruit concentrate, acidifier, cultures.
  • the products comprise protein, preferably in an amount of from 0.5 to 10 wt%.
  • the most preferred protein is milk protein such as derived from fresh milk, yoghurt, quark, skimmed milk powder, whey powder, caseinate, cream.
  • An alternative protein source is vegetable protein, preferably soy protein.
  • Preferred products comprise a living culture.
  • a living culture is a culture which has not been inactivated by a heating step and which continues fermentation in pack. Such cultures are also referred to as yoghurt cultures and probiotics. Suitable cultures include Lactobacillus Bulgaricus, Lactobacillus rhawnosus, Streptococcus thermopilus, Bifidobacterium, Lactobacillus casei . It was found that such cultures may also positively contribute to off taste reduction.
  • the products are concentrated drinks comprising up to 5 wt% fat, from 1.5 to 4 wt% sterol and/or stanol fatty acid ester, milk protein, water and sugar or a sugar replacer (sugar being preferred) and preferably emulsifier.
  • Even more preferred those products are acidified, preferably fermented products, with a pH in the range from 3.8 to 6, preferably from 4 to 5.
  • the products may be prepared by any suitable process.
  • a preferred process comprises the steps of preparing a premix of the tocopherol and the sterol and/or stanol fatty acid ester. This premix is added to the aqueous phase. The other ingredients may be added at any stage of the process.
  • the invention is illustrated by the following non-limiting examples .
  • ⁇ -tocopherol was derived from a tocopherol mixture comprising 60% ⁇ -tocopherol and 24% ⁇ -tocopherol .
  • the ⁇ -tocopherol was derived from a tocopherol mixture comprising 86% ⁇ -tocopherol.
  • a premix was prepared comprising milk, cream and water at a temperature of about 60 °C. Tocopherols and sterolester was weighed and mixed with a spoon. The aqueous mixture was subjected to vigorous stirring in a TurraxTM. While the Turrax TM was run at low speed of about 3500 rpm, the powder mix of sugar and skim milk powder was mixed in, followed by the sterolester composition. Mixing was continued at higher speed for some more minutes. The mixture was then heated to 75 °C and pasteurised. Next the mix was homogenised at 200 bar and cooled to fermentation temperature of about 43 °C. A separately prepared yoghurt culture was used to inoculate the product. Fermentation was continued until a pH of about 4.3 was reached. The fermented product was sturred and homogenised at about 50 bar before it was filled into sterile containers. The product was cooled and stored at 5 °C.
  • a trained panel of experts evaluated the products directly after preparation and after storage for 3 weeks at 5 °C.
  • the panel was trained on tasting off flavor and compared the products to a commercially available drink yoghurt of the brand ActimelTM, which is free of sterol or stanol ester.
  • the products were scored as good, acceptable or bad.
  • Comparative example "C” was evaluated as bad by all participants for the sample directly after preparation and after 3 weeks of storage .
  • Product according to example 1 was evaluated as good by 25% of the test panel and acceptable by 50% of the test panel directly after preparation. It was found good by about 33% of the test panel and acceptable by about 35% of the test panel after 3 weeks.
  • Product of example 2 was evaluated as good by 38% of the panel and acceptable by 40% of the panel directly after preparation. After 3 weeks 50% of the panel found it good and 50% acceptable.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Dairy Products (AREA)

Abstract

L'invention concerne des produits à phase continue aqueuse comprenant un tocophérol spécifique combiné à un ester d'acide gras de stérol et/ou un ester d'acide gras de stanol. Ces produits conservent leur saveur lorsqu'ils sont stockés.
PCT/EP2005/002878 2004-04-16 2005-03-16 Produit a phase continue aqueuse comprenant un sterol ou un stanolester et un tocopherol WO2005099484A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05716179A EP1742545A1 (fr) 2004-04-16 2005-03-16 Produit à phase aqueuse continue contenant des stérols ou stanols estérifiés et tocophérol
AU2005232369A AU2005232369A1 (en) 2004-04-16 2005-03-16 Water continuous product comprising sterol or stanolester and a tocopherol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04076167.8 2004-04-16
EP04076167 2004-04-16

Publications (1)

Publication Number Publication Date
WO2005099484A1 true WO2005099484A1 (fr) 2005-10-27

Family

ID=34928163

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/002878 WO2005099484A1 (fr) 2004-04-16 2005-03-16 Produit a phase continue aqueuse comprenant un sterol ou un stanolester et un tocopherol

Country Status (3)

Country Link
EP (1) EP1742545A1 (fr)
AU (1) AU2005232369A1 (fr)
WO (1) WO2005099484A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070429A1 (fr) 2007-12-13 2009-06-17 Cognis IP Management GmbH Stabilisation oxydative de stérols et esters de stérols
JP2014209885A (ja) * 2013-04-19 2014-11-13 株式会社Adeka 可塑性油脂組成物

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839458A1 (fr) * 1996-11-05 1998-05-06 Riken Vitamin Co., Ltd. Compositions contenant des phytosterols et leur production
WO1999063841A1 (fr) * 1998-06-05 1999-12-16 Forbes Medi-Tech Inc. Compositions renfermant du phytosterol et/ou du phytostanol a solubilite et dispersibilite ameliorees
WO2000015201A2 (fr) * 1998-09-10 2000-03-23 Forbes Medi-Tech Inc. COMPOSITIONS COMPRENANT UN OU PLUSIEURS PHYTOSTEROLS, PHYTOSTANOLS, OU LEURS MELANGES, UN OU PLUSIEURS TOCOTRIENOLS, $G(ab, $G(b), $G(d) OU $G(g), OU LEURS DERIVES, UTILISATION DE CES COMPOSITIONS POUR TRAITER OU PREVENIR L'AFFECTION CARDIO-VASCULAIRE, SES ATTEINTES SOUS-JACENTES ET D'AUTRES ETATS PATHOLOGIQUES
WO2000041491A2 (fr) * 1999-01-15 2000-07-20 Nutrahealth Ltd (Uk) Aliments ou boissons modifies ou additifs pour aliments et boissons
EP1108364A2 (fr) * 1999-12-15 2001-06-20 McNEIL-PPC, INC. Alcools à chaine longue en mélange dans des composés stéroliques
WO2002034072A2 (fr) * 2000-10-24 2002-05-02 Novartis Nutrition Ag Combinaison antioxydante synergistique de tocols delta et de polyphenols
WO2002060272A1 (fr) * 2001-01-29 2002-08-08 Redeem, Inc. Huile comestible anticholesterol
WO2002072035A2 (fr) * 2001-03-14 2002-09-19 Lipogenics, Inc. Compositions anti-inflammatoires et procedes d'utilisation
WO2002094303A1 (fr) * 2001-05-18 2002-11-28 Rimonest Ltd. Produits a base de grenade permettant d'ameliorer la sante et procede d'utilisation de ces derniers
WO2003055324A1 (fr) * 2001-12-21 2003-07-10 Raisio Benecol Oy Composition contenant un hydrolysat de proteines et un sterol vegetal servant a ameliorer le profil de lipide serique et a prevenir l'atherosclerose

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839458A1 (fr) * 1996-11-05 1998-05-06 Riken Vitamin Co., Ltd. Compositions contenant des phytosterols et leur production
WO1999063841A1 (fr) * 1998-06-05 1999-12-16 Forbes Medi-Tech Inc. Compositions renfermant du phytosterol et/ou du phytostanol a solubilite et dispersibilite ameliorees
WO2000015201A2 (fr) * 1998-09-10 2000-03-23 Forbes Medi-Tech Inc. COMPOSITIONS COMPRENANT UN OU PLUSIEURS PHYTOSTEROLS, PHYTOSTANOLS, OU LEURS MELANGES, UN OU PLUSIEURS TOCOTRIENOLS, $G(ab, $G(b), $G(d) OU $G(g), OU LEURS DERIVES, UTILISATION DE CES COMPOSITIONS POUR TRAITER OU PREVENIR L'AFFECTION CARDIO-VASCULAIRE, SES ATTEINTES SOUS-JACENTES ET D'AUTRES ETATS PATHOLOGIQUES
WO2000041491A2 (fr) * 1999-01-15 2000-07-20 Nutrahealth Ltd (Uk) Aliments ou boissons modifies ou additifs pour aliments et boissons
EP1108364A2 (fr) * 1999-12-15 2001-06-20 McNEIL-PPC, INC. Alcools à chaine longue en mélange dans des composés stéroliques
WO2002034072A2 (fr) * 2000-10-24 2002-05-02 Novartis Nutrition Ag Combinaison antioxydante synergistique de tocols delta et de polyphenols
WO2002060272A1 (fr) * 2001-01-29 2002-08-08 Redeem, Inc. Huile comestible anticholesterol
WO2002072035A2 (fr) * 2001-03-14 2002-09-19 Lipogenics, Inc. Compositions anti-inflammatoires et procedes d'utilisation
WO2002094303A1 (fr) * 2001-05-18 2002-11-28 Rimonest Ltd. Produits a base de grenade permettant d'ameliorer la sante et procede d'utilisation de ces derniers
WO2003055324A1 (fr) * 2001-12-21 2003-07-10 Raisio Benecol Oy Composition contenant un hydrolysat de proteines et un sterol vegetal servant a ameliorer le profil de lipide serique et a prevenir l'atherosclerose

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070429A1 (fr) 2007-12-13 2009-06-17 Cognis IP Management GmbH Stabilisation oxydative de stérols et esters de stérols
JP2014209885A (ja) * 2013-04-19 2014-11-13 株式会社Adeka 可塑性油脂組成物

Also Published As

Publication number Publication date
EP1742545A1 (fr) 2007-01-17
AU2005232369A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
AU2006212485B2 (en) Food products comprising hydrolysed milk solids with improved taste
AU2002325486B2 (en) Composition for lowering blood cholesterol
US9144545B2 (en) Sterol ester powder
JPH11146757A (ja) 水性分散液又は懸濁液
JP2012191944A (ja) 苦味、酸味及び／又は渋味をマスクした食用製品
CA2570334A1 (fr) Confiserie congelee
WO2003077679A1 (fr) Aliment contenant du sterol vegetal et methode de preparation dudit aliment
JP2013518565A (ja) 飲料
AU2003249894B2 (en) Phytosterols or phytostanols and their use in food products
US11806352B2 (en) Theobromine for increasing HDL-cholesterol
US20070141123A1 (en) Emulsions comprising non-esterified phytosterols in the aqueous phase
EP1742545A1 (fr) Produit à phase aqueuse continue contenant des stérols ou stanols estérifiés et tocophérol
US20060188635A1 (en) Food product comprising phytosterols
MXPA05004461A (es) Emulsion de agua en aceite que comprende esteres de esterol.
AU2007222696B2 (en) Sterol esters having short-chained fatty acids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005716179

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200607642

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005232369

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005232369

Country of ref document: AU

Date of ref document: 20050316

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005232369

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005716179

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005716179

Country of ref document: EP